Related Experiment Video
Updated: Feb 4, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
Discovery and lead identification of quinazoline-based BRD4 inhibitors
Shyh-Ming Yang1, Daniel J Urban1, Makoto Yoshioka2
1National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.
Abstract:
A new series of quinazoline-based analogs as potent bromodomain-containing protein 4 (BRD4) inhibitors is described. The structure-activity relationships on 2- and 4-position of quinazoline ring, and the substitution at 6-position that mimic the acetylated lysine are discussed. A co-crystallized structure of 48 (CN750) with BRD4 (BD1) including key inhibitor-protein interactions is also highlighted. Together with preliminary rodent pharmacokinetic results, a new lead (65, CN427) is identified which is suitable for further lead optimization.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Drug Discovery: Overview
Phase-lead and Phase-lag Controllers
Dipeptidyl Peptidase 4 Inhibitors
Time and frequency -Domain Interpretation of Phase-lead Control
The design of phase-lead control involves the strategic placement of poles and zeros to balance steady-state error and system...
Antihypertensive Drugs: Direct Renin Inhibitors

